SNY Stock Recent News

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows.

Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, February 13, 2025. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d'Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient efficacy in preventing invasive E.

French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which would be done between now and the end of December.

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025, Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, preferably through block trades and in the open market with the purpose of cancellation.

MASSY, France--(BUSINESS WIRE)--MITEM PHARMA, a French-based pharmaceutical company dedicated to Drugs of Major Therapeutic Interest (DMTI), is pleased to announce that it has acquired the rights to FLISINT®, an infectious disease DMTI, from SANOFI WINTHROP INDUSTRIE (Gentilly - France). FLISINT® (fumagillin) is recognised as the only treatment capable of overcoming Enterocytozoon bieneusi microsporidia infections. This opportunistic germ develops in clinical situations of immunosuppression (e.

L'Oréal will raise €3 billion by selling 29.6 million Sanofi shares back to Sanofi to cut its stake in the drugmaker.  The French cosmetics giant, which also owns Garnier and Lancome, sold the shares back to Sanofi for €101.5 apiece as part of an effort to "optimize" its balance sheet after a recent acquisition spree.

AGREEMENT BETWEEN L'ORÉAL AND SANOFI FOR THE REPURCHASE BY SANOFI OF 2.3% OF ITS OWN SHARES HELD BY L'ORÉAL

Sanofi announces buy back of shares from L'Oréal Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L'Oréal.